CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Combination of Lopinavir /Ritonavir and Interferon beta-1bWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug458 Leflunomide Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

This is a placebo-controlled clinical trial to assess the feasibility, efficacy and safety of a combination of lopinavir/ritonavir and Interferon beta-1b in hospitalized patients with MERS.

NCT02845843 Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b Drug: Placebo
MeSH:Coronavirus Infections

Primary Outcomes

Measure: 90-day mortality

Time: 90-day

Secondary Outcomes

Measure: Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors)

Time: 28 days

Measure: RT-PCR cycle threshold value in the lower respiratory samples

Time: At randomization and every 3 days afterwards, until 3 consecutive samples are negative or reaching a maximum of 90 days

Measure: Sequential organ failure assessment (SOFA) scores

Time: Days 1, 3, 5, 7, 14, and 28

Measure: Length of stay in ICU

Time: Up to one year from enrollment

Measure: Length of stay in hospital

Time: Up to one year from enrollment

Measure: Duration of mechanical ventilation

Time: Up to one year from enrollment

Description: Infections will be reported as per the NHSN 2016 definitions, as number of events per devise day or ICU day as appropriate.

Measure: Hospital-acquired infections as assessed by the NHSN 2016 definitions

Time: Up to one year from enrollment

Measure: Serial chest radiograph findings

Time: 28 day

Measure: Number of Patients with Adverse drug reactions related to the treatment

Time: From enrollment to 28 day

Measure: Karnofsky Performance Scale

Time: 90-day

Measure: ICU mortality

Time: Up to one year from enrollment

Measure: Hospital mortality

Time: Up to one year from enrollment

Measure: 28-day mortality

Time: 28-day

No related HPO nodes (Using clinical trials)